First Tracks Biotherapeutics, Inc.
TRAX Nasdaq
SEC CIK 2091349
Follow First Tracks Biotherapeutics
Weekly email: filings, results
Net income
−$31.4M
+25.1% vs same quarter last year
EPS, diluted
−$0.88
+41.3% vs same quarter last year
Operating cash flow
−$17.1M
+44.4% vs same quarter last year
Operating income
−$32.8M
+27.1% vs same quarter last year
Source: SEC XBRL filings · latest filing